Disc Medicine closed at $83.28 on Nov 4, up 2.61%, 11.5% below its 52-week closing high. Volume of 1.4M shares was 0.92× its 20-day average (close to normal).
Split-adjusted performance: +35.1% over one month, +21.3% over six months, -1.7% over one year.
Short interest was 7.5M shares at the Oct 15 settlement, up 2.6% from the prior report (22.8% of float, 10.6 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| IRONDisc Medicine | $83.28 | +2.61% | +21.3% | — | — | — | $3.70B | |
| ACADAcadia Pharmaceuticals | $21.47 | +4.38% | 0.0% | +16.4% | 10.2% | 9.7 | $3.70B | Compare |
| AMLXAmylyx Pharmaceuticals | $29.40 | +0.68% | +83.1% | — | — | — | $3.69B | Compare |
| PBLSParabilis Medicines | $30.36 | +3.79% | — | — | −45239.9% | — | $3.75B | Compare |
| OGNOrganon & | $13.83 | −0.14% | +3.1% | −1.7% | 10.4% | 17.1 | $3.63B | Compare |
| XENEXenon Pharmaceuticals | $39.19 | +2.51% | −33.1% | — | — | — | $3.80B | Compare |
| VKTXViking Therapeutics | $27.97 | +7.21% | −13.4% | — | — | — | $3.57B | Compare |
| TNGXTango Therapeutics | $23.18 | +0.04% | −1.9% | −100.0% | — | — | $3.91B | Compare |
| DYNDyne Therapeutics | $18.54 | +2.71% | −1.6% | — | — | — | $3.46B | Compare |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
